Suchergebnisse - "Kelland, L R"

Guidelines for the welfare and use of animals in cancer research von Workman, P, Aboagye, E O, Balkwill, F, Balmain, A, Bruder, G, Chaplin, D J, Double, J A, Everitt, J, Farningham, D A H, Glennie, M J, Kelland, L R, Robinson, V, Stratford, I J, Tozer, G M, Watson, S, Wedge, S R, Eccles, S A

“… Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and …”
Volltext

“Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development von Kelland, L.R.

“… Human tumour xenografts implanted subcutaneously (s.c.) into immunosuppressed mice have played a significant role in preclinical anticancer drug development …”
Volltext

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90 von Kelland, L R, Sharp, S Y, Rogers, P M, Myers, T G, Workman, P

“… To our knowledge, 17-allylamino,17-demethoxygeldanamycin (17AAG) is the first inhibitor of heat shock protein 90 (Hsp90) to enter a phase I clinical trial in …”
Weitere Angaben

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026 von Nutley, B P, Smith, N F, Hayes, A, Kelland, L R, Brunton, L, Golding, B T, Smith, G C M, Martin, N M B, Workman, P, Raynaud, F I

“… In this study we investigated the in vitro time dependence of radiosensitisation, pharmacokinetics and metabolism of NU7026, a novel inhibitor of the DNA …”
Volltext

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473 von Holford, J, Sharp, SY, Murrer, BA, Abrams, M, Kelland, LR

“… A novel sterically hindered platinum complex, AMD473 [cis-aminedichloro(2-methylpyridine) platinum (II)], has been selected for phase I clinical trials due to …”
Volltext

A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity von Mann, J, Baron, A, Opoku-Boahen, Y, Johansson, E, Parkinson, G, Kelland, LR, Neidle, S

“… The synthesis and evaluation of the novel head-to-head bisbenzimidazole compound 2,2-bis[4'-(3 " -dimethylamino- 1 " -propyloxy)phenyl]-5,5-bi-1H-benzimidazole …”
Weitere Angaben

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status von Kelland, Lloyd R

“… This review focuses on the clinical development of the prototype broad spectrum inhibitor of cyclin-dependent kinases (CDKs), flavopiridol, now undergoing …”
Volltext

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma von Beale, P J, Rogers, P, Boxall, F, Sharp, S Y, Kelland, L R

“… The expression of the BCL-2 family proteins, BCL-2, BAX, BCL XL and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a …”
Volltext

Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin von Sharp, S.Y, O'Neill, C.F, Rogers, P, Boxall, F.E, Kelland, L.R

“… Four models of acquired resistance to the clinically-used platinum drug, oxaliplatin, have been established using human tumour cell lines in vitro; two colon …”
Volltext

Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity von Gregson, S J, Howard, P W, Hartley, J A, Brooks, N A, Adams, L J, Jenkins, T C, Kelland, L R, Thurston, D E

“… A novel sequence-selective pyrrolobenzodiazepine (PBD) dimer 5 (SJG-136) has been developed that comprises two C2-exo-methylene-substituted DC-81 (3) subunits …”
Weitere Angaben

Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines von Holford, J., Beale, P.J., Boxall, F.E., Sharp, S.Y., Kelland, L.R.

“… Acquired drug resistance to the sterically hindered platinum drug ZD0473 (formerly known as JM473 and AMD473) and currently being tested in phase I clinical …”
Volltext

BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin von Manzotti, C, Pratesi, G, Menta, E, Di Domenico, R, Cavalletti, E, Fiebig, H H, Kelland, L R, Farrell, N, Polizzi, D, Supino, R, Pezzoni, G, Zunino, F

“… Multinuclear platinum complexes represent a new class of anticancer agents, distinct in terms of DNA binding features and the profile of antitumor activity …”
Weitere Angaben

Induction of apoptosis by a novel copper-based anticancer compound, Casiopeina II, in L1210 murine leukaemia and CH1 human ovarian carcinoma cells von De Vizcaya-Ruiz, A., Rivero-Muller, A., Ruiz-Ramirez, L., Kass, G.E.N., Kelland, L.R., Orr, R.M., Dobrota, M.

“… The activity of casiopeina II [Cu(1,4-dimethyl-1,10-phenanthroline)(glycine)NO 3], a novel anticancer agent, was tested in two cell lines, L1210 murine …”
Volltext

Variation in RNA expression and genomic DNA content acquired during cell culture von Hiorns, L R, Bradshaw, T D, Skelton, L A, Yu, Q, Kelland, L R, Leyland-Jones, B

“… Specific chromosomal abnormalities are increasingly recognised to be associated with particular tumour subtypes. These cytogenetic abnormalities define the …”
Volltext

Synthesis, characterization, and cytotoxicity of trifunctional dinuclear platinum complexes: comparison of effects of geometry and polyfunctionality on biological activity von Qu, Y, Rauter, H, Soares Fontes, A P, Bandarage, R, Kelland, L R, Farrell, N

“… The synthesis of two new isomeric trifunctional dinuclear platinum complexes of formula [¿PtCl(NH(3))(2)¿micro-NH(2)(CH(2))(6)NH(2)-¿PtCl(2)(N H(3))¿](+) (1, …”
Weitere Angaben

2,7-disubstituted amidofluorenone derivatives as inhibitors of human telomerase von Perry, PJ, Read, MA, Davies, RT, Gowan, SM, Reszka, AP, Wood, AA, Kelland, LR, Neidle, S

“… Telomerase is a major new target for the rational design of novel anticancer agents. We have previously identified anthraquinone-based molecules capable of …”
Weitere Angaben

Human telomerase inhibition by substituted acridine derivatives von Harrison, R. John, Gowan, Sharon M., Kelland, Lloyd R., Neidle, Stephen

“… A series of 3,6-disubstituted acridine derivatives have been rationally designed as telomerase inhibitors. They have been designed on the basis that inhibition …”
Volltext

An update on satraplatin: the first orally available platinum anticancer drug von Kelland, Lloyd R

“… This update focuses on the clinical development of the first orally available platinum-containing anticancer drug, satraplatin (JM216, BMS 182751, BMY 45594) …”
Volltext

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer von McKeage, M J, Raynaud, F, Ward, J, Berry, C, O'Dell, D, Kelland, L R, Murrer, B, Santabárabara, P, Harrap, K R, Judson, I R

“… We aimed to determine the maximum-tolerated dose (MTD) clinical toxicities, pharmacokinetics, and pharmacodynamics of oral JM216 given once daily for 5 days to …”
Weitere Angaben

Farnesyl transferase inhibitors--a novel therapy for breast cancer von Johnston, S R, Kelland, L R

“… Inhibitors of the enzyme farnesyl protein transferase prevent a key step in the post-translational processing of the Ras protein, and were developed initially …”
Weitere Angaben